
-
Arcturus Therapeutics NasdaqGM:ARCT Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Location: 10628 Science Center Drive, San Diego, CA, 92121, United States | Website: https://arcturusrx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
171M
Cash
216.9M
Avg Qtr Burn
-22.33M
Short % of Float
21.67%
Insider Ownership
7.89%
Institutional Own.
92.48%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KOSTAIVE ® (ARCT-154) Details COVID-19 | BLA Submission | |
ARCT-032 Details Cystic fibrosis, Lung disease, Ornithine transcarbmylase deficiency Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
ARCT-810 Details Ornithine transcarbmylase deficiency, Urea cycle disorder Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
ARCT-2138 Details Influenza | Phase 1b Data readout | |
ARCT-2304 Details H5N1 avian influenza | Phase 1 Data readout | |
ARCT-021 Details COVID-19 | Failed Discontinued |